Structure and in vitro effects of the 3 active compounds and the related inactive compound. (A) The active compounds along with the related inactive compound are as follows: SSCL02446, 2-[5-chloro-2-(heptyloxy)phenyl]-1-(1H-imidazol-1-yl)-2-propanol; SSCL02447, 2-[5-chloro-2-(octyloxy)phenyl]-1-(1H-imidazol-1-yl)-2-propanol; SSCL02448, 2-[5-chloro-2-(nonyloxy)phenyl]-1-(1H-imidazol-1-yl)-2-propanol; and SSCL02444: 2-[2-(2-fluorobenzyloxy)phenyl]-1-(1H-imidazol-1-yl)-2-pentanol. (B) G-CSF–induced cell proliferation. The BAF/GCSFR cells were cultured for 48 hours with varying concentrations of rhG-CSF, SSCL02446, SSCL02447, SSCL02448, or SSCL02444. Cell proliferation was measured with WST-1/1-methoxy-5-methylphenazinium methyl sulfate (PMS) as substrate (n = 5; mean). Standard errors of the mean were less than 5% and were therefore omitted. (C) IL-3–dependent cell proliferation. BAF/B03 cells were cultured for 48 hours in media containing various concentrations of rmIL-3, rhG-CSF, or the small compounds. (D) EPO-dependent cell proliferation. The BAF/EPOR cell line was cultured for 48 hours with various concentrations of rhEPO, rhG-CSF, or the small compounds. (E) TPO-dependent cell proliferation. The BAF/TPOR cell line was cultured for 48 hours with various concentrations of rhTPO, rhG-CSF, or the small compounds. (F) IL-10–dependent cell proliferation. The BAF/IL10R cell line was cultured for 48 hours with various concentrations of rhIL-10, rhG-CSF, or the small compounds. (G) IL-2–dependent cell proliferation. CTLL-2 cells were cultured for 48 hours in medium containing various concentrations of rmIL-2 or the small compounds.